HD-OPM Archive

Can plaque shrink? What the trials show

Coronary plaque can shrink in randomized trials, mostly the soft, lipid-rich part, and mostly when LDL cholesterol is pushed low. This summary walks through which drugs, diets and other interventions achieved it, by how much, and how far the evidence can be trusted.

17 min read53 group posts cited52 studies discussed4 chartsEvidence through Nov 2026AI Summary of posts by Louis Nervegna and Gokhan Can
Key takeaways
  • Six statin trials reported total plaque volume falling roughly 5% to 17% from baseline, and the FLOWPROMOTE trial reported about 14% at an average LDL of about 70 mg/dL versus about 21% at about 42 mg/dL.
  • Regression of total plaque generally starts once achieved LDL-C falls below roughly 90 mg/dL, with more regression the lower LDL goes.
  • Much of what shrinks is soft, lipid-rich plaque, while calcified plaque often stays the same or rises, so a rising calcium score does not by itself mean failure.
  • A 1% absolute fall in percent atheroma volume has been linked to about 20% fewer major cardiovascular events, but that is an association, not proof.
  • Diet and weight loss can add to drug effects. In DISCO-CT, a DASH diet plus statins reversed about 40 mm3 of soft plaque in a year on CT, 2.4 times the statin-only reversal.
  • Evidence is strongest for LDL-lowering drugs, then for a handful of single trials (colchicine, high-dose EPA, exercise, DASH diet), and weakest for supplements and for case reports.
In this summary
  1. What plaque is and how "shrinking" is measured
  2. What the evidence shows
  3. Which LDL level is needed?
  4. Nuances, controversies and common misconceptions
  5. What this means for you
  6. Frequently asked questions
  7. The evidence behind this summary

For many years, clogged arteries were thought of as a one-way street. The group's posts argue that this is no longer accurate: in randomized trials that image the artery wall directly, plaque volume has measurably gone down in people treated with statins, ezetimibe, PCSK9 inhibitors and several other approaches.12 Louis Nervegna, one of the group's admins, describes plaque reversal as "real" and says it is common in the first few years after starting a statin.13

The size of the effect depends on how it is measured, which drug or diet is used, and above all how low LDL cholesterol gets. Reductions of a few percent of plaque volume are typical, double-digit reductions have been reported in some trials, and the part that shrinks is mainly the soft, fatty, rupture-prone core rather than hard calcium.45

This summary flags where posts disagree and separates randomized evidence from single-patient stories. It is educational, not medical advice, and the group's admins recommend discussing any treatment decision with your own doctor.

5–17%fall in total plaque volume from baseline in six randomized statin trials46
~90 mg/dLachieved LDL-C below which total plaque generally starts to regress47
2.4×more soft-plaque reversal when a DASH diet was added to statins in DISCO-CT8
~20%fewer major cardiac events linked to each 1% fall in percent atheroma volume (an association)910

What plaque is and how "shrinking" is measured

Atherosclerotic plaque is the buildup of cholesterol-rich material, inflammatory cells and, eventually, calcium inside the artery wall. Plaque is not one thing. Researchers separate it into soft or non-calcified plaque (fatty and fibrous tissue with a lipid core) and hard calcified plaque. Louis stresses that the soft plaque is the dangerous kind and that calcified plaque is more of a marker.14

Regression is reported in a few different ways, and mixing them up is the most common source of confusion:

  • Total atheroma volume (TAV) is the total volume of plaque in the segment scanned, soft and calcified together. A "6.5% reduction in TAV" means the plaque is 6.5% smaller than at baseline, a relative change.7
  • Percent atheroma volume (PAV) is the share of the scanned vessel volume occupied by plaque. A PAV of 15% means 15% of the scanned artery is plaque. Changes in PAV are usually quoted in absolute percentage points, so "PAV fell 1%" is a much smaller number than "TAV fell 17%".915
  • Non-calcified plaque volume (NCPV) counts only the soft component and is usually given in cubic millimetres (mm3).8

Intravascular ultrasound (IVUS) places a tiny ultrasound camera inside the artery and is described as the gold standard for imaging plaque.1617 Coronary CT angiography (CCTA) measures plaque non-invasively and can detect it long before it narrows the channel.418 Optical coherence tomography (OCT) is used to measure the thickness of the fibrous cap that covers a plaque, and near-infrared spectroscopy (NIRS) measures lipid content.1519

Ordinary x-ray angiography only shows the outline of the blood channel (the lumen), not the plaque in the wall. Early plaque makes the wall bulge outward, so a "normal" angiogram can hide a large plaque burden (Glagov remodeling).20 This is why Louis treats older angiography-based trials with caution.18

What the evidence shows

Statins: the largest body of evidence

Louis lists six randomized trials of statins and the reduction in total plaque volume each showed relative to baseline: COSMOS about 5%, SATURN about 5.5%, ASTEROID about 6.5%, IBIS-4 about 7.5%, STABLE about 8% and JAPAN-ACS about 17%. He attributes the percentages to a figure in a 2022 JACC state-of-the-art review of plaque regression, and notes they were measured by IVUS or CT angiography.46 Gokhan Can's earlier review summarizes the same literature as statins lowering total atheroma volume by 0% to 20%, with high-intensity atorvastatin and rosuvastatin looking more effective than lower doses.21 The JACC review is quoted as concluding that statins induce plaque regression in a dose-dependent manner and in proportion to the LDL-C reduction.12

Six statin trials, plaque down 5% to 17%Fall in total plaque volume from baseline in randomized statin trials, measured by IVUS or CT angiography, as listed by Louis from a 2022 JACC review
COSMOSabout −5%
SATURNabout −5.5%
ASTEROIDabout −6.5%
IBIS-4about −7.5%
STABLEabout −8%
JAPAN-ACSabout −17%
Approximate values; different patients, statins, doses and durations, so not a head-to-head comparison. Source: 46
Show data
Value
COSMOSabout −5%
SATURNabout −5.5%
ASTEROIDabout −6.5%
IBIS-4about −7.5%
STABLEabout −8%
JAPAN-ACSabout −17%

Individual trial figures, as the group has posted them, are smaller because many are absolute PAV changes:

  • SATURN (2011): high-dose atorvastatin 80 mg reduced PAV by 0.99% over 24 months in 1,039 patients.22 A separate analysis posted by Gokhan reports rosuvastatin 40 mg versus atorvastatin 80 mg, with PAV changes of -1.22% versus -0.99% (not significantly different) and somewhat larger TAV reductions with rosuvastatin.10
  • ASTEROID (2006): rosuvastatin 40 mg reduced PAV by 0.98% over 24 months in 507 patients.22
  • COSMOS (2016): PAV fell 0.95% versus 0.05% with placebo over 52 weeks in 418 patients, as described in the post.22

Louis often calls Japan-ACS the standout. About 300 patients with acute coronary syndrome at 33 centers in Japan were randomized to pitavastatin 4 mg or atorvastatin 20 mg a day. After 8 to 12 months, plaque volume in the non-culprit arteries (excluding the blockage that caused the event) changed by -16.9% and -18.1% respectively, measured by IVUS, with average LDL falling from about 130 to about 80-85 mg/dL.1623 Patients one standard deviation above the mean regressed by about 31-32%, and one patient by more than 70%.16 A different summary in the group lists Japan-ACS as -5.1% versus -0.7% for strong statins versus non-statin therapy in 252 patients, so figures for this trial differ from post to post.22

Japan-ACS: percent change in plaque volume for each of 251 patients plotted against follow-up LDL-C. Most patients regressed, the spread was wide, and the circled patient shrank by more than 70%.
Japan-ACS: percent change in plaque volume for each of 251 patients plotted against follow-up LDL-C. Most patients regressed, the spread was wide, and the circled patient shrank by more than 70%.16

A 2021 meta-analysis shared by Gokhan pooled 31 studies and 4,997 patients and found significantly lower TAV and PAV with lipid-lowering therapy, with LDL below 80 mg/dL and HDL above 45 mg/dL associated with maximal regression.10

The newest addition is FLOWPROMOTE (JAMA Cardiology, 2026), a randomized trial in 104 statin-naive patients in Denmark with stable coronary disease imaged by CCTA at baseline, 9 and 18 months.24 Atorvastatin 40 mg reached an average LDL of about 70 mg/dL and total plaque volume fell about 13.6%. Rosuvastatin 40 mg plus ezetimibe 10 mg reached about 42.5 mg/dL and total plaque fell about 21.1%, with non-calcified plaque down 28.2% versus 20%.111325 The authors reported a linear relationship between achieved LDL and the amount of regression.11 The share of patients with regression of non-calcified plaque was given as 98% versus 77% in one post and about 90% in the lower-LDL group in another, so check the paper for the exact figure.1113 A caution noted in one summary: FLOWPROMOTE was an imaging study, not a trial of heart attacks or survival.25

FLOWPROMOTE: lower LDL, more regressionChange in plaque volume on CT angiography over 18 months, 104 statin-naive patients with stable coronary disease
Atorvastatin 40 mg (LDL ~70)Rosuvastatin 40 mg + ezetimibe (LDL ~42.5)
Total plaque volume-13.6%-21.1%
Non-calcified (soft) plaque-20%-28.2%
An imaging trial; it did not measure heart attacks or survival. Source: 111325
Show data
Atorvastatin 40 mg (LDL ~70)Rosuvastatin 40 mg + ezetimibe (LDL ~42.5)
Total plaque volume-13.6%-21.1%
Non-calcified (soft) plaque-20%-28.2%

Ezetimibe and PCSK9 inhibitors

Ezetimibe is a non-statin drug that blocks cholesterol absorption. Gokhan's review notes at least six IVUS trials in which adding ezetimibe to optimal therapy gave numerically greater regression (from -2.9% to -13.9% in total atheroma volume), though not every trial reached statistical significance.21 In a summary originally posted by group member Daniel Chong, the ZEUS trial in diabetic patients with acute coronary syndrome found plaque shrank 13.9% when ezetimibe was added to a statin versus 5.1% with statin alone, and PRECISE-IVUS reported PAV falling 1.4% with 78% of patients showing regression.2

PCSK9 inhibitors (injectable antibodies that sharply lower LDL) have also been imaged on top of statins. In GLAGOV, evolocumab plus statin brought LDL to about 37 mg/dL and PAV fell 0.95% versus a 0.05% rise on statin alone, and TAV fell 2.9% versus 0.4% over 76 weeks.2627 Gokhan's summary lists a non-significant reduction with alirocumab in ODYSSEY J-IVUS over 36 weeks, and a further trial in which PAV fell 1.01% versus a 0.26% rise.26 One caution on naming: the same post and Louis's list place IBIS-4 in different categories, and another post gives the name PRECISE-IVUS to different trial details (ezetimibe in one post, evolocumab in another). Readers should check the primary papers rather than rely on the labels.2426

Absolute PAV changes are small but point the right wayChange in percent atheroma volume (percentage points) with the added drug versus the comparison group, IVUS trials
Added drugComparison
GLAGOV: evolocumab + statin vs statin alone (76 weeks)-0.950.05
PCSK9 trial in Gokhan's summary-1.010.26
PERISCOPE: pioglitazone vs glimepiride (18 months, type 2 diabetes)-0.160.73
Absolute PAV changes look much smaller than relative changes in total plaque volume. Different trials and durations. Source: 262728
Show data
Added drugComparison
GLAGOV: evolocumab + statin vs statin alone (76 weeks)-0.950.05
PCSK9 trial in Gokhan's summary-1.010.26
PERISCOPE: pioglitazone vs glimepiride (18 months, type 2 diabetes)-0.160.73

The YELLOW-III trial gave 137 patients maximum statin therapy and then evolocumab 140 mg every two weeks for 26 weeks. It reported fibrous cap thickness up more than 30% on OCT, PAV down by an absolute 1.38% on IVUS, and a TAV fall from 137.2 to about 131 mm3 (-4.4%) at an average LDL of about 39 mg/dL, with the shrinkage driven mainly by the lipid core.1529 Louis calls this the "melting butter" sign.30 The earlier YELLOW study reported falling lipid-core content within 7 to 8 weeks of intensive rosuvastatin, which Louis describes as stabilization rather than bulk shrinkage.19 His lists of regression trials also name FOURIER (2017) and HUYGENS (2021) alongside ASTEROID, GLAGOV and YELLOW-III, without giving their numbers.31

Colchicine, high-dose EPA, pioglitazone

  • Colchicine (an anti-inflammatory drug): in a small randomized CT study led by Matthew Budoff, colchicine 0.5 mg daily lowered percent atheroma volume by more than 1% over one year and lowered CRP, with trends toward regression of non-calcified plaque and slower progression of calcified plaque.32 Gokhan's review describes the same study as open-label and notes that total atheroma volume changes were similar, with the benefit mainly in low-attenuation plaque, so the evidence is promising but limited.21
  • High-dose EPA (icosapent ethyl, 4 g/day): the EVAPORATE trial enrolled 80 people with coronary disease, most with diabetes and on statins, with triglycerides of 135 to 499 mg/dL. After 18 months the EPA group had less unstable plaque and a lower total plaque volume than placebo.33 An earlier summary gives -17% in vulnerable plaque and points out that total plaque did not shrink much, so the type of plaque changed more than the amount.2 The posts repeatedly warn that doses this high can raise the risk of atrial fibrillation and advise talking to a doctor first.3334
  • Pioglitazone (a diabetes drug): in PERISCOPE, 543 patients with type 2 diabetes had PAV change of -0.16% on pioglitazone versus +0.73% on glimepiride over 18 months.28

Diet, weight loss and exercise

Louis lists six randomized diet trials that showed plaque regression: Lifestyle Heart (1990, Ornish diet), STARS (1992, AHA diet), SCRIP (1994, AHA diet), PREDIMED (2013, Mediterranean), CORDIOPREV (2021, Mediterranean) and DISCO (2021, DASH).3536 He notes that none used a purely vegan diet; all were mostly plant-based, emphasizing fruits, vegetables, legumes, whole grains, nuts, olive oil and fish, and limiting refined foods, butter, fatty red meat and heavy alcohol.35

The DISCO-CT trial is the one Louis highlights most. Ninety-two non-diabetic patients with non-obstructive coronary disease were randomized to intensive medical therapy including statins, with or without dietitian-led DASH advice and more activity. Non-calcified plaque fell by 51.3 mm3 in the diet group versus 21.3 mm3 with medication alone, which is 2.4 times more.837 The trial lasted 66 weeks. Louis scaled the diet-group result to one year (about -39.5 mm3) and compared it with a typical at-risk person's growth of about 5 mm3 a year, giving his "eight years in one year" headline, and is explicit that the benchmark is a typical American, not each person's own prior growth.838 The diet was about 30% fat, mostly unsaturated, not low-fat, and calcified plaque did not rise in either group.839

DISCO-CT: adding a DASH diet more than doubled soft-plaque reversalFall in non-calcified plaque volume over 66 weeks, 92 non-diabetic patients with non-obstructive coronary disease, all on intensive medical therapy including statins
DASH diet + medication−51.3 mm³
Medication alone−21.3 mm³
Louis scales the diet-group result to about −39.5 mm³ per year, against a typical at-risk person's growth of about 5 mm³ a year. Source: 837
Show data
mm³
DASH diet + medication−51.3 mm³
Medication alone−21.3 mm³

Weight loss: Louis says about 30 lb of weight loss has been shown to reverse soft plaque, citing the DIRECT-Carotid trial of low-fat, Mediterranean and low-carbohydrate diets.364041

Exercise: the CENIT trial of supervised high-intensity interval training reported PAV falling 1.2% per year with no change in controls.2 Exercise on top of LDL below 70 mg/dL appears additive in a review Louis shared.42

Which LDL level is needed?

The group returns often to LDL thresholds. Louis's reading of the JACC figure is that regression of total plaque begins once LDL-C falls below roughly 90 mg/dL.47 A Medscape interview he quoted says that at an LDL of about 80 mg/dL roughly half of subjects had regression, and below 60 mg/dL 90% of regressable, lipid-rich plaques regressed.43 Gokhan summarizes a 2019 JACC review as saying progression stops below 70 mg/dL and regression generally needs levels below 60.44 A Cleveland Clinic cardiologist, in a clip Louis shared, says plaque volume can fall by up to 24% when LDL is pushed below 70 mg/dL.45 Louis also describes a 2004 intensive-statin IVUS trial that drove LDL to about 60 mg/dL.17

Lower LDL, more regression across imaging trials
From the 2022 JACC review: change in total plaque volume against achieved LDL-C (mmol/L) in statin, ezetimibe and PCSK9 inhibitor trials; most trials at lower LDL-C show plaque shrinking.
From the 2022 JACC review: change in total plaque volume against achieved LDL-C (mmol/L) in statin, ezetimibe and PCSK9 inhibitor trials; most trials at lower LDL-C show plaque shrinking.7
Median change in total and percent atheroma volume against average on-treatment LDL-C (mg/dL) in IVUS trials such as SATURN, ASTEROID and REVERSAL: the lower the LDL-C, the more the plaque fell.
Median change in total and percent atheroma volume against average on-treatment LDL-C (mg/dL) in IVUS trials such as SATURN, ASTEROID and REVERSAL: the lower the LDL-C, the more the plaque fell.9

These numbers differ because they come from different trials, drugs and imaging methods. The consistent message is that lower achieved LDL goes with more regression,11 although Japan-ACS also showed large regression at about 80-85 mg/dL.16

Nuances, controversies and common misconceptions

Soft plaque shrinks, calcium often does not

In statin trials, fibrous and calcified plaque volumes tend to rise while non-calcified, fibrofatty and necrotic-core volumes fall.12 Louis explains that total plaque can fall even when calcium stays the same or increases, because soft plaque loss is large enough.4 Gokhan describes a "statin paradox", in which lipid-rich plaques regress into denser, calcified ones, and argues that PCSK9 inhibitors appear to regress plaque without the same calcification surge (GLAGOV, PACMAN-AMI, and smaller CAC studies).27 Louis shares the finding but notes that no outcome trial of PCSK9 inhibitors alone exists and that whether it matters long term is still debated.46

For readers tracking a coronary calcium (CAC) score, a post Louis shared explains why the score can rise while treatment is working.47 Louis argues that calcified plaque mostly acts as a proxy for how much soft plaque exists, that obsession with lowering CAC is misguided, and that the goal should be reversing soft plaque. He adds that nobody knows whether removing calcium would be beneficial or harmful without outcome trials.14 He also says a high CAC score is not a death sentence, and that exercise, weight loss and LDL below 70 mg/dL all help.40

Does shrinking plaque mean fewer heart attacks?

The posts repeatedly cite that each 1% reduction in PAV is associated with about a 20% reduction in major adverse cardiac events.910 A 2023 JAMA Cardiology meta-analysis of 7,407 patients across 23 studies is quoted as finding about 19% lower odds per percentage-point drop, with the explicit caveat that these are associations, not proof that a given amount of regression produces a specific risk reduction.13 Louis himself stresses that what ultimately matters is heart attacks, strokes and death, which is why outcome trials are needed.14 A review Gokhan summarized reports that plaques progressing rapidly before rupture carried a 28-fold higher likelihood of an acute coronary event,44 and CT-based plaque burden often predicts events better than the degree of stenosis.48

The Ornish trial and measurement error

Louis argues that the Ornish Lifestyle Heart Trial's reported lumen widening of 2.1% at one year and 3.4% at five years is below what x-ray angiography can reliably resolve (about 0.2 mm), and that the technique never measures plaque itself, so some of the reported reversal may be measurement error.18 This is the opinion of Louis and the academic cardiologists he cites, not a finding from the trial. He still counts the result as similar to PREDIMED and CORDIOPREV and smaller than DISCO-CT, and notes the Esselstyn diet has not been tested in randomized trials.36

Keto-CTA as a cautionary contrast

Keto-CTA was a one-year cohort of lean people on a ketogenic diet with very high LDL (about 254 mg/dL), in which PAV rose from 1.6% to 2.4% on average.49 Louis argues in a letter to JACC that a pre-specified outcome was omitted from the main text.50 These are one admin's critiques.

Case reports and anecdotes

Members share individual stories: severe LAD stenosis that became mild over four years on atorvastatin 10 mg,51 paired CT scans from the same scanner and radiologist,52 soft LAD plaque resolving on 6 g/day of EPA without a statin,34 and a carotid case with salmon, niacin and low-dose rosuvastatin.53 Louis calls the statin case an outlier, and the EPA member flagged atrial fibrillation and bleeding risks. These are single patients and cannot show what will happen to anyone else.

Fasting, supplements and unproven claims

Louis considers fasting biologically plausible through autophagy, but the plaque evidence he and a clinician he shared describe is anecdotal.41 Gokhan's review rates aged garlic extract, Centella asiatica, pine bark extract, nattokinase and a plant-based diet as promising but needing rigorous trials, and L-arginine and vitamin K2 as unclear.21 Louis calls supplement evidence "a gamble" based on small human or animal studies and advises sticking to safe options that do not conflict with proven treatments.36

What this means for you

  • Know what is being measured. Ask whether a number is a relative change in TAV, an absolute change in PAV, or a soft-plaque (NCPV) change in mm3.49
  • LDL lowering has the deepest evidence. The group's admins point to LDL levels around 70 mg/dL or lower as where progression often stops and regression becomes more likely, and to ezetimibe and PCSK9 inhibitors as ways to go lower; this is a conversation to have with your own doctor.114044
  • Diet and weight loss appear additive to medication in DISCO-CT, and the diets tested were Mediterranean, DASH and similar mostly plant-based patterns, not necessarily vegan.835
  • Do not judge progress by the CAC score alone, since it can rise while soft plaque falls. Louis favors imaging that measures plaque directly, such as CT angiography, if you want to track changes.1847
  • High-dose fish oil: the posts warn of atrial fibrillation risk and recommend discussing it with a doctor first.33
  • Louis criticizes online claims that statins do nothing, pointing to the randomized imaging trials, and cautions against unproven interventions.2351

Frequently asked questions

Do statins really reverse plaque?

According to the trials in the group's posts, yes, on average, in the soft plaque. Six randomized trials show total plaque falling about 5% to 17% from baseline.4 Individual response varies, and Louis calls the most dramatic case an outlier.1651

How fast can plaque change?

Reported timeframes range from 7 to 8 weeks for lipid-core content (YELLOW)19 and about six months for fibrous cap and volume changes (YELLOW-III)15, to 8 to 12 months in Japan-ACS16 and 18 months in FLOWPROMOTE.11

Does a vegan diet have to be used to reverse plaque?

Louis says no: of the six diet trials showing regression, none used a purely vegan diet, even the Ornish trial allowed egg whites and non-fat dairy. He adds that anyone getting good results on a vegan diet is welcome to share.35

Does shrinking plaque prove fewer heart attacks?

No. The 20% per 1% PAV figure is an association from meta-analysis and earlier trials, and FLOWPROMOTE did not measure clinical events.1325

The evidence behind this summary52 studies · 2 meta-analyses · 38 trials · 5 observational

The 53 group posts cited above discuss 52 studies and sources. Their mix of study designs shows how much rests on randomized trials and meta-analyses, which can show cause and effect, and how much on observational, lab or animal work, which mostly cannot.

Meta-analyses 2Randomized trials 38Observational studies 5Reviews & guidelines 2Other sources 5

Strongest evidence discussed

All 52 studies and sources
Sources from the group (53)
  1. Plaque regression is real: Louis links the randomized trials of drugs, colchicine and EPA Louis Nervegna · Sep 05, 2026 · Facebook
  2. Evidence that plaque can shrink: CENIT, PRECISE-IVUS, ZEUS, EVAPORATE and GLAGOV Louis Nervegna · Jun 25, 2025 · Facebook
  3. Six statin trials show 5 to 17% total plaque reversal, with the best results at lowest LDL Louis Nervegna · Oct 31, 2026 · Facebook
  4. Six randomized trials show statins reduce total plaque volume 5-17% from baseline Louis Nervegna · Mar 02, 2026 · Facebook
  5. Keto trial showed worse plaque progression; DASH plus statins regressed plaque Louis Nervegna · Oct 05, 2025 · Facebook
  6. Six RCTs show statins reverse total plaque volume by 5% to 17% Louis Nervegna · Aug 25, 2026 · Facebook
  7. Plaque volume begins to regress once LDL-C falls below about 90 mg/dL across RCTs Louis Nervegna · Aug 12, 2025 · Facebook
  8. DISCO-CT: DASH diet plus statins reversed soft plaque by about 40 mm3 in a year Louis Nervegna · Aug 18, 2025 · Facebook
  9. SATURN: high-dose statins reversed plaque 1-2%; each 1% PAV cut means 20% fewer events Louis Nervegna · Aug 18, 2025 · Facebook
  10. Meta-analysis: lipid-lowering therapy regresses coronary plaque (Li 2021, SATURN) Gokhan Can · Nov 25, 2023 · Facebook
  11. FLOWPROMOTE: lower achieved LDL gave more plaque regression, 21.1% at LDL near 43 Louis Nervegna · Oct 31, 2026 · Facebook
  12. What to do with a high coronary calcium CT result: Joel Kahn's guide Gokhan Can · Nov 17, 2023 · Facebook
  13. FLOWPROMOTE: rosuvastatin plus ezetimibe shrank total coronary plaque 21% in 18 months Louis Nervegna · Nov 14, 2026 · Facebook
  14. Calcified plaque is a marker, the goal should be reversing soft plaque Louis Nervegna · Aug 16, 2025 · Facebook
  15. YELLOW-III: statin plus evolocumab thickened fibrous caps over 30% in 6 months Louis Nervegna · Mar 22, 2026 · Facebook
  16. Japan-ACS: pitavastatin and atorvastatin both regressed coronary plaque by about 17-18% Louis Nervegna · Sep 13, 2025 · Facebook
  17. Intensive statin reversed atherosclerosis on IVUS in a 2004 Cleveland Clinic-led trial Louis Nervegna · Dec 23, 2023 · Facebook
  18. Ornish trial's 'plaque reversal' may be x-ray angiography measurement error Louis Nervegna · Dec 05, 2025 · Facebook
  19. YELLOW trials: intensive rosuvastatin cut lipid-core plaque within 7-8 weeks Louis Nervegna · Aug 15, 2026 · Facebook
  20. A normal angiogram can hide large plaque burden because of Glagov remodeling Louis Nervegna · Dec 13, 2025 · Facebook
  21. Plaque reduction: statins, PCSK9 inhibitors and ezetimibe have the strongest evidence Gokhan Can · May 18, 2024 · Facebook
  22. Statin plaque regression RCTs: SATURN, REVERSAL, ASTEROID, COSMOS, JAPAN-ACS Louis Nervegna · Jan 18, 2025 · Facebook
  23. Japan-ACS: modest statin doses cut non-culprit plaque volume by about 17-18% Louis Nervegna · Sep 18, 2025 · Facebook
  24. FLOWPROMOTE: rosuvastatin plus ezetimibe vs atorvastatin for plaque regression Louis Nervegna · Nov 07, 2026 · Facebook
  25. FLOWPROMOTE: LDL near 40 mg/dL on statin plus ezetimibe cut total plaque 21% in 18 months Louis Nervegna · Oct 31, 2026 · Facebook
  26. PCSK9 inhibitors on top of statins regressed plaque in GLAGOV and PRECISE-IVUS Gokhan Can · Dec 25, 2023 · Facebook
  27. PCSK9 inhibitors regress plaque without the calcification surge seen with statins Gokhan Can · Jan 01, 2026 · Facebook
  28. Pioglitazone slowed coronary plaque progression and shrank necrotic core in diabetics Gokhan Can · Jan 14, 2025 · Facebook
  29. YELLOW-III reversed total atheroma volume 4.4% in 6 months at LDL of about 39 mg/dL Louis Nervegna · Mar 23, 2026 · Facebook
  30. YELLOW-III 'melting butter' sign: lipid core shrinks and fibrous cap thickens in 6 months Louis Nervegna · Mar 22, 2026 · Facebook
  31. Trials showing plaque regression: ASTEROID, GLAGOV, FOURIER, HUYGENS, YELLOW-III Louis Nervegna · Aug 12, 2026 · Facebook
  32. Colchicine 0.5 mg cut plaque volume by over 1% in one year on CT angiography (Budoff) Louis Nervegna · May 11, 2025 · Facebook
  33. EVAPORATE: high-dose EPA reversed plaque in patients with triglycerides above 135 mg/dL Louis Nervegna · May 04, 2026 · Facebook
  34. Group member reports 'widowmaker' soft plaque regression on 6 g/day EPA, citing EVAPORATE Louis Nervegna · May 04, 2026 · Facebook
  35. Six RCTs have shown diet can reverse plaque, and none used a purely vegan diet Louis Nervegna · Oct 24, 2025 · Facebook
  36. Six strategies shown to regress plaque in human randomized trials Louis Nervegna · Feb 27, 2025 · Facebook
  37. DISCO-CT: DASH diet plus statins reversed ~40 mm3 of soft plaque in one year Louis Nervegna · Nov 14, 2026 · Facebook
  38. DISCO-CT: DASH diet plus statins reversed ~40 mm3 of soft plaque in a year on CT Louis Nervegna · Aug 12, 2026 · Facebook
  39. Five RCT-backed ways to reverse plaque; DASH in DISCO-CT was not low fat Louis Nervegna · May 03, 2026 · Facebook
  40. High CAC score is not a death sentence: weight loss, LDL below 70, diet and exercise Louis Nervegna · May 28, 2025 · Facebook
  41. Can fasting reverse plaque? Autophagy makes it plausible but evidence is indirect Louis Nervegna · Jun 29, 2026 · Facebook
  42. Exercise, including HIIT, can reduce coronary plaque burden and add to LDL lowering Louis Nervegna · Jul 10, 2025 · Facebook
  43. Plaque regression is common when LDL falls to about 80 or below (Medscape interview) Louis Nervegna · Jun 14, 2025 · Facebook
  44. JACC review: rapid plaque progression precedes rupture and LDL below 70 mg/dL halts it Gokhan Can · Jan 02, 2026 · Facebook
  45. Statins reverse total and soft plaque once LDL is below 70 mg/dL, Cleveland Clinic says Louis Nervegna · Sep 04, 2025 · Facebook
  46. PCSK9 inhibitors regress soft plaque without the calcification surge seen with statins Louis Nervegna · Jul 02, 2026 · Facebook
  47. Calcification paradox: why CAC scores can rise as the heart gets healthier on statins Louis Nervegna · May 01, 2026 · Facebook
  48. CT angiography plaque burden often predicts events better than stenosis severity Louis Nervegna · Jun 09, 2026 · Facebook
  49. Keto-CTA (LMHR): plaque volume rose 25-100% in one year across CAC and risk subgroups Louis Nervegna · Apr 09, 2025 · Facebook
  50. Letter to JACC: Keto-CTA omitted pre-specified outcome, a 43% rise in non-calcified plaque Louis Nervegna · Apr 21, 2025 · Facebook
  51. Case report: 10 mg atorvastatin cleared most of a severe LAD blockage over 4 years Louis Nervegna · Oct 06, 2025 · Facebook
  52. Member's paired CT angiograms show major plaque reversal, same machine and radiologist Louis Nervegna · Aug 12, 2026 · Facebook
  53. Case: carotid plaque regression with salmon, niacin and low-dose rosuvastatin Louis Nervegna · Dec 23, 2023 · Facebook

Keep exploring

Related research summaries

Topics and hashtags in this summary